Quratis

Quratis EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Quratis (348080.KQ) as of Oct 18, 2026 is -8.01. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -9.88 — a change of -18.98% (higher).

EV/FCF

-8.01

YoY

-18.98%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Quratis is 2025 -8.01 . EV/FCF (Enterprise Value to Free Cash Flow) of Quratis was 2024 -9.88 . It decreases by -18.98% higher compared to the previous year.

The Quratis EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2020
-3.99 KRW
Jan 1, 2021
-5.59 KRW
Jan 1, 2022
-8.55 KRW
Jan 1, 2023
-7.53 KRW
Jan 1, 2024
-9.88 KRW
Jan 1, 2025
-8.01 KRW
The Quratis EV/FCF history
YEAREV/FCFYoY
-8.01-18.98%
-9.88+31.21%
-7.53-11.86%
-8.55+52.76%
-5.59+40.27%
-3.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quratis Stock analysis

What does Quratis do? Quratis Inc is a biotechnology company based in Seoul, South Korea, operating within the Health Care sector. The company went public on June 15, 2023, with its stock listed under the ticker 348080.KQ and ISIN KR734808080003. Quratis focuses on research and development in the pharmaceutical industry, specifically developing medicine and pharmaceutical products. The company is involved in the manufacture and sale of vaccines and peptide nucleic acid complexes. It also provides Cell Penetrating Peptide (CPP) platform services. Quratis is engaged in the development and research of vaccines, including tuberculosis vaccines for adults and adolescents and COVID-19 vaccines. The company has 91 employees and maintains a website at http://quratis.com/. Quratis operates in the biotechnology industry, emphasizing innovation in vaccine development and pharmaceutical research. Its headquarters are located in Seoul, South Korea, and it is active in the development of novel therapeutic solutions for global health challenges. The company's activities span from research to commercialization, with a focus on advancing medical treatments through biotechnology. Quratis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quratis stock

EV/FCF (Enterprise Value to Free Cash Flow) of Quratis is -8.01 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Quratis changed from -9.88 to -8.01, representing a -18.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Quratis since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Quratis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Quratis

All Key Metrics — Quratis